Monitoring of monoclonal antibodies for COVID-19: weekly report published

AIFA publishes the results of the monitoring related to monoclonal antibodies for the treatment of COVID-19 currently available.

AIFA: Anna Rosa Marra appointed Interim Director General

Anna Rosa Marra has been appointed Interim Director General of the Italian Medicines Agency by Decree of the Minister of Health.

Biosimilar medicines in Italy: AIFA reports updated

The analyses of consumption and expenditure trends and regional variability are online.

Latest initiatives to reduce antibiotic resistance in Italy presented

After the recommendations for general medicine and hospitals on resistant infections, the Italian Medicines Agency presented the most recent initiatives of the AIFA-OPERA CTS Working Group to reduce antibiotic resistance in Italy.

In fact, the “Manuale antibiotici AWaRe”, the Italian edition of the volume presented by the World Health Organisation (WHO) in December 2022 ('The WHO AWaRe Antibiotic Book') has been published.

From the WHO global recommendations, the ten most easily observed syndromes in adults and children were also selected, calibrated and adapted to the epidemiological context and medicine availability in Italy.  

The contents have been collected in two publications 'Treatment of the most frequent community bacterial infections in adults/children - according to the principles of "The WHO AWaRe Antibiotic Book"' (soon available) and will be freely accessible on the Agency's website, also via App.
The presentation was attended by Director General Nicola Magrini, Evelina Tacconelli (University of Verona), Patrizia Popoli (President of the Scientific Technical Committee, CTS) and Federico Marchetti (U.O. Paediatrics and Neonatology, Ravenna).